Why the study?
Does immunoadsorption improve cardiac function in patients with dilated cardiomyopathy?
Does immunoadsorption improve cardiac function in patients with dilated cardiomyopathy?
Immunoadsorption represents a potential therapeutic approach for dilated cardiomyopathy by targeting the humoral immune system and removing cardiac autoantibodies.
May support immunoadsorption in DCM; leaves open confirmation by randomized trials before clinical adoption.
Dilated cardiomyopathy (DCM) is a myocardial disease characterized by progressive depression of myocardial contractile function, and by ventricular dilatation. Abnormalities of the cellular and humoral immune system are present in a subset of patients with myocarditis and DCM. A number of various cardiac autoantibodies against cardiac cellular proteins have been identified in patients with myocarditis and DCM. Recent clinical studies showed that removal of antibodies by immunoadsorption improves cardiac function of patients with DCM indicating that activation of the humoral immune system may play a functional role in DCM.
No takes yet. Share an insight, caveat, or question.
Stephan B. Felix (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: